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In an attempt to elucidate the relationship between DNA adduct formation and tumorigenesis, DNA adducts were measured in the livers and bladders
of mice during chronic exposure to several different doses of 2-acetylaminofluorene (2-AAF) and 4-aminobiphenyl (4-ABP). Continuous oral adminis-
tration of these compounds for 4 weeks produced an increase in DNA adduct formation during the first 2 weeks, followed by a plateau, which pre-
sumably occurred because the rate of adduct removal offset the rate of adduct formation. The quantity of DNA adducts present at equilibrium
correlated directly with the carcinogen concentration; therefore, when exposure was continued for 4 weeks, DNA adducts that reflected the plateau
level at each dose could be expressed as a function of dose. Liver and bladder DNA adduct profiles thus obtained during administration of multiple
doses of 2-AAF (to female mice) and 4-ABP (to male and female mice) were compared to profiles for tumor incidences obtained during lifetime
exposures to the same doses. These experiments demonstrated similar profiles for DNA adduct formation and tumorigenesis in liver. In the bladder,
DNA adducts were linear, but tumors only appeared at the higher doses in conjunction with cell proliferation. In addition to these aromatic amines,
similar data are available for aflatoxin B1, diethylnitrosamine, and (methyinitrosamino)-1-(3-pyridyl)-1-butanone (also known as nicotine-derived
nitrosoketone). Of the nine different biological situations (carcinogen/species/sex/organ) for which data are available, correlations between steady-
state DNA adduct levels and tumorigenic response at the different doses were linear in five of the nine biological models. When the relationship
between DNA adduct formation and tumor incidence was not linear, the profiles observed were considered to be the result of tissue-specific phe-
nomena such as metabolic activation, cell proliferation, or cytotoxicity. - Environ Health Perspect 102(Suppl 6):161-165 (1994)
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Introduction
Among the earliest cellular changes caused
by chemical carcinogens are the formation
ofDNAadducts, which are covalent binding
products of carcinogens with DNA (1-3).
The weight ofevidence from animal exper-
imentation suggests that DNA adduct for-
mation may constitute events that are
necessary but not sufficient for tumorigene-
sis (3,4). DNA adduct studies that employ
chronic carcinogen dosing over a range of
carcinogen concentrations are relatively
rare. However, most experiments of this
type have demonstrated an early increase in
adduct accumulation with time of expo-
sure, followed by a plateau observed when
the rate ofadduct formation is offset by the
rate ofadduct removal (5-9). The plateau,
indicating steady-state conditions, is fre-
quently reached before 4 weeks ofcontinu-
ous carcinogen administration. The level of
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DNA adducts observed at the plateau
phase usually correlates directly with the
concentration of carcinogen in the diet
(6,7,10) (Figure 1). Therefore, at a particular
time (e.g., 4 weeks) ofcontinuous carcino-
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gen administration, it is possible to obtain
a profile for steady state DNA adduct levels
expressed as a function ofdifferent concen-
trations of carcinogen chronically given
(Figure 2).
Days of Feeding AAF
Figure 1. Female BALB/c mice were fed 2-AAF in the diet at concentrations of 30 (0) and 150 (0) mg/kg body
weight for3, 7, 14, 21, 28, 56, or 112 days; dG-C8-AFadducts were measured in liver DNA by radioimmunoassay.
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Figure 2. (Al Tumor incidence at 24 months and (B) dG-C8-AF at 28 days for livers (@)and bladders (0) of female
BALB/c mice given continuous administration of 2-AAF in the diet. Concentrations of dietary 2-AAF for the tumor
study were 0, 30, 35, 45, 60, 75, 100, and 150 ppm, and for the DNA adduct study were 0, 5, 10, 15, 30, 45, 60, 75,
Most rodent tumorigenesis studies are
conducted by lifetime carcinogen adminis-
tration, but few of these are large enough
to include many dose levels. In a few
instances, rodent tumor incidences induced
by lifetime carcinogen administration
(24-36 months) have been compared to
DNA adduct levels in target tissues at early
times (1-2 months) of chronic exposure,
over a wide range ofdoses. The profiles of
adducts and tumorigenesis thus obtained
are instructive in elucidating factors rele-
vant to carcinogen-DNA interactions and
tumor incidence in animals.
This review will discuss individual
experiments in which chronic lifetime
exposure over a broad dose range has been
employed to induce tumors, and DNA
adducts have been measured in target tis-
sues ofrodents given similar dosing for 1 to
2 months. The aromatic amines considered
include 2-acetylaminofluorene (2-AAF)
and 4-aminobiphenyl (4-ABP). These
compounds were studied in livers and blad-
ders of male and female mice. Other com-
pounds for which similar experiments will
be described include aflatoxin B1 (AFBI),
diethylnitrosamine (DEN) and 4-(methyl-
nitrosamino)- 1-(3-pyridyl)- 1-butanone
(known as a nicotine-derived nitrosoketone
or NNK). Overall patterns of tumor inci-
dence and DNA adduct formation will be
presented and significant aspects of tissue
specificity will be discussed.
Aromatic Amines
In experimental animals, major target
organs for tumor induction from aromatic
amines include the liver and urinary bladder.
In these two tissues in the mouse, 2-AAF
(10) and 4-ABP (11) each form essentially
only one DNA adduct, through covalent
linkage ofthe amine nitrogen to the C8 of
guanine. Thus, the tumorigenic effects of
2-AAF in mouse liver and bladder appear
to be associated only with the N-
(deoxyguanosin-8-yl)-2-aminofluorene
(dG-C8-AF). Similarly, the tumorigenic
effects of 4-ABP appear to be associated
primarily with N-(deoxyguanosin-8-yl)-4-
aminobiphenyl (dG-C8-ABP).
In the mid-1970s an exceedingly large
tumorigenicity experiment was conducted
by feeding 2-AAF to approximately 24,000
female BALB/c mice (12). The compound
was given at seven different dietary concen-
trations, and animals were killed at varying
times between 9 and 33 months. Incidences
of benign and malignant tumors obtained
in both the liver and the urinary bladder at
24 months are shown in Figure 2A. In the
livers of untreated animals the incidence of
adenomas and carcinomas was 2.6%, and
tumors increased linearly with concentra-
tion of 2-AAF in the diet, reaching 40% at
the highest dose. In the bladder, by com-
parison, the tumor profile was nonlinear
with a spontaneous rate of0.3% that rose
slowly to 2% at 75 ppm ofdietary 2-AAF,
and increased dramatically thereafter,
resulting in incidences of 17 and 75% at
doses of 100 and 150 ppm, respectively. A
similar pattern ofbladder hyperplasia pre-
ceded the bladder tumorigenesis in the
EDOI study, which suggested that cell pro-
liferation caused, or at least accompanied,
the increase in tumorigenesis. This was fur-
ther investigated by Cohen and Ellwein
(13), who quantified cell proliferation asso-
ciated with bladder hyperplasia at the same
doses and hypothesized that a marked
increase in proliferation at 100 and 150
mg/kg diet contributed to the elevated
tumor incidence at these doses. In a parallel
DNA adduct study (10), mice were fed 2-
AAF in the diet at the doses used in the
EDOI study plus 3 lower doses (Figure
2B). DNA adducts increased linearly with
dose in both tissues; however, the bladder
DNA adduct levels were consistently 2- to
4-fold higher than those observed in the
liver. Thus, high levels of DNA adducts in
the bladder appeared to be necessary for
tumorigenesis but were not sufficient until
the bladder cell proliferation rate reached a
critical level, at doses above 75 mg/kg diet
(13).
Another aromatic amine, 4-ABP, was
chronically administered to male BALB/c
mice at 6 doses between 7 and 220 ppm in
the drinking water in both tumorigenesis
and DNA adduct studies. Liver and bladder
tumor incidences at 24 months (14) and
DNA adducts at 28 days are shown in
Figure 3. At the highest doses, 110 and
220 ppm, the liver tumor incidence did
not reach 10% (Figure 3A), whereas in the
bladder, the tumor increase was not signifi-
cant at doses up to 28 ppm but was essen-
tially linear from 55 to 220 ppm, reaching
82%. Bladder tumorigenesis was only sig-
nificant at doses for which the incidence of
bladder hyperplasia was >85% (14), sug-
gesting that cell proliferation is a prerequi-
site for tumorigenesis in these male mice.
In both tissues, DNA adducts (Figure 3B3)
increased linearly with dose and correlated
well with tumorigenesis (i.e., adduct levels
were 2- to 3-fold higher in bladder where
the tumor incidence was also high, com-
pared to liver where the tumor incidence
was low). The relatively low DNA adduct
levels in the male mouse liver (up to 125
fmoles/pg DNA) may reflect the presence
ofhighly induced detoxification pathways.
For example, there may be extensive N-glu-
curonidation of N-hydroxy-4-ABP, which
could result in a larger effective dose to the
bladder; concomitantly, less 4-ABP would
be available for activation pathways leading
to DNA adduct formation in the liver. In
addition, kidney microsomes from male
BALB/c mice apparently have a 10-fold
greater capacity to metabolize the related
aromatic amine, 3-methoxy-4-aminoazo-
benzene, to mutagenic metabolites than
they do kidney microsomes from female
mice (15). This sex-specific difference in
metabolism may contribute to the high
tumorigenesis and DNA adduct formation
seen in bladders ofmale mice.
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Figure 3. (A) Tumor incidence at 24 months and (B) dG-C8-ABP at 28 days for livers (I) and bladders (0) of male
BALB/c mice given continuous administration of 4-ABP in the drinking water. Concentrations of 4-ABP for the
tumorand DNA adduct studies were 0, 7, 14, 28, 55, 110, and 220 ppm.
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Figure 4. (A) Tumor incidence at 24 months and (B) dG-C8-ABP at 28 days for livers (0) and bladders (0) of
female BALB/c mice given continuous administration of 4-ABP in the drinking water. Concentrations of 4-ABP for
the tumor and DNA adduct studies were 0, 7, 19, 38, 75, 150, and 300 ppm.
Similar tumorigenesis and DNA adduct
studies were conducted in female mice
given 4-ABP in the drinking water at 6
doses between 7 and 300 ppm. The dose
range for females was higher than that for
males because of lower toxicity. The liver
tumor incidence at 24 months (14)
increased linearly with dose for the first 5
doses but was the same at 150 and 300
ppm (Figure 4A). The DNA adduct levels
at 28 days (11) increased linearly for the
first 4 doses and less than linearly at 150
and 300 ppm (Figure 4B). Thus, a satura-
tion of the metabolic activation pathways
leading to DNA adduct formation may
have occurred in liver at 150 ppm and
above. A factor confounding this interpre-
tation is the considerable toxicity associated
with the 300-ppm dose, with fewer than
50% ofthe mice surviving 2 years of treat-
ment. The low adduct accumulation (<75
fmoles/pg DNA) (11) and low tumor inci-
dence (<20%) (14) in female mouse blad-
der may reflect the reduced availability of
compound for detoxification resulting
from extensive activation and DNA adduct
formation in the liver. Or they may result
from the low metabolic capacity ofBALB/c
female kidney microsomes described above
(15). Since the opposite metabolic rela-
tionship is seen in male mice (Figure 3),
hormonal influences may contribute to the
balance between activation and detoxifica-
tion. There was significant bladder hyper-
plasia at 75 to 300 ppm (14), but in the
absence of high levels of DNA adducts
there was apparently insufficient stimulus
for tumorigenesis.
Other Chemical Carcinogens
In three other situations, extensive data exist
for tumorigenesis developing after chronic
lifetime administration ofmultiple doses of
chemical carcinogens and can be compared
to the concomitant DNA adduct data for
chronic dosing at similar concentrations for
1 to 2 months. Although these compounds
are not aromatic amines, the data will be
discussed because they contribute to con-
clusions that can be drawn from a complete
overview of the area. The compounds in
question are AFB1, DEN, and NNK.
A linear increase in liver tumors at 24
months was observed in male Fischer rats
given AFB1 at five doses between 1 and 50
ppm in the drinking water (16), with the
liver tumor incidence being 80% at the
highest dose. A subsequent study by Buss
et al. (17) investigated hepatic DNA
adduct formation by administering radiola-
beled AFBI to male Fischer rats in the
drinking water at doses of 0.02, 0.6, and
20 ppm for 8 weeks. The increase in DNA
adduct formation was linear, with the high-
est DNA adduct level being 2.7 fmoles/jg
DNA. Thus, in the case ofchronic admin-
istration ofAFB1 to rats, liver tumorigene-
sis is essentially linear, as is DNA adduct
formation over a similar dose range. This
situation is depicted in Figure 5, tumor and
adduct curves B. The high carcinogenic
potency of the aflatoxins may result in
tumor formation at concentrations that do
not saturate metabolic pathways, stimulate
cell proliferation, or induce extensive toxicity.
Fifteen different doses ofDEN, ranging
between 0.033 and 16.9 ppm, were given
in the drinking water in an extensive life-
time tumorigenesis study involving 1140
male Colworth (Wistar) rats (18). The life-
time liver tumor incidence, as a function of
dose, was not linear, but approached a
plateau at the higher doses. The experi-
mental design of a DNA adduct study
(6,19), measuring 04-ethyldeoxythymi-
dine (04-Et-dT) in liver DNA, was similar.
This adduct accumulated in hepatocytes of
rats continuously exposed to DEN and is
considered to be the major promutagenic
adduct responsible for the induction of
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Figure 5. Schematic representation of supralinear (A),
linear (B), sublinear (C) and low (D) profiles for DNA
adduct formation (-) and tumorigenesis (--- ) in
rodents given chronic administration of chemical car-
cinogens at multiple dose levels. Tumorigenesis is for
lifetime exposure and DNA adduct data are obtained at
i to 2 months.
hepatocellular carcinomas (6). The DNA
adduct profile obtained with DEN was
similar to the tumor profile, and both are
depicted in tumor and adduct curves A of
Figure 5 [designated by Swenberg (7,19) as
supralinear curves]. This lack of linearity
may result from a lower efficiency of
adduct formation or an increased loss of
the adduct. The latter hypothesis was sup-
ported experimentally. Astudy was done in
which hepatocytes from rats given 40 ppm
of DEN were shown to have a 43-fold
increase in cell proliferation, as compared
to controls (20). Thus, toxicity-related cell
proliferation may be responsible for the
lack oflinearity ofthe DNA adduct profile
at higher doses. The similar phenomenon
in the tumorigenicity study may also be
due to toxicity (18).
The nicotine-derived nitrosoketone,
NNK, produces lung tumors as a result of
chronic exposure in rats (21). Studies by
Belinsky et al. (21) indicate that Clara cells
apeear to accumulate the highest levels of
O -methyldeoxyguanosine (O -Me-dG), a
procarcinogenic lesion. Therefore, lung
tumorigenesis in male Fischer rats given
subcutaneous injections ofNNK 3 times a
week for 20 weeks was compared with
DNA adduct formation in the Clara cells
of animals treated similarly for 4 weeks
(21). Six doses were chosen, between 0.03
and 50 mg/kg bw, for the tumorigenicity
studies, and lung tumors were evaluated at
31 months. The lung tumor incidence
increased rapidly at low doses to give a
53% tumor incidence at 1 mg NNK/kg
bw, and then more slowly to yield 73 and
87% tumors at 10 and 50 mg NNK/kg
bw, respectively. For the DNA adduct
studies, five doses were chosen between 0.1
and 50 mg/kg bw, and the profile for
adduct formation was strikingly similar to
that for tumorigenesis. The tumor and
DNA adduct curves for NNK were supra-
linear (Figure 5, A curves), similar to
DEN, but the increases at the lower doses
were more pronounced. The biphasic
nature of both tumor and DNA adduct
curves was postulated to be caused by a
high-affinity pathway that activates low
doses ofNNK to methylate DNA, forming
the promutagenic adduct 06-Me-dG. This
pathway presumably becomes saturated at
the higher doses (8,22). In addition, in
animals given NNK doses higher than 1
mg/kg bw, there was significant evidence of
lung hyperplasia and mild necrosis that
may have contributed to the lack oflinear-
ity of DNA adducts with increasing dose
(21).
Tumor-Adduct Profile
Correlations
The different types ofrelationships between
dose and tumorigenesis, and dose and DNA
adduct formation, observed during chronic
carcinogen administration at multiple
doses in rodents are categorized in Figure 5
and summarized in Table 1. In addition to
the linear category (B curves), the supralin-
ear (A curves) and sublinear (C curves) cat-
egories originally defined by Swenberg
(7,19), an additional category (D curves),
termed "Low," is added here. Category D
refers to situations in which, at all doses
studied, there were few tumors and the levels
ofDNA adducts were low.
The data presented here, and summa-
rized in Table 1, include nine different per-
mutations of carcinogen, species, sex, and
organ. Some issues that will be discussed
include whether the tumorigenesis and
DNA adduct profiles are both linear or
nonlinear with dose, whether there are
enough DNA adducts to produce tumors,
and whether the tumorigenesis and DNA
adduct profiles are similar to or different
from each other.
In the simplest situation, both DNA
adducts and tumors were linear with dose.
This was observed with 2-AAF in female
mouse liver and with AFBI in male rat
liver. Representing two out ofthe nine pos-
sibilities, this straightforward relationship
(Figure 5, B curves) is not the mostfrequent.
In two instances, with 4-ABP in male
mouse liver and 4-ABP in the female
mouse bladder, the DNA adduct levels
were relatively low and the tumor inci-
dence never reached 20%. This suggests
that tumorigenic transformation, with or
without toxicity or cell proliferation, might
have occurred with higher DNA adduct
levels. It implies the existence ofeffective
hepatic detoxification pathways that may
result in reduced activation to DNA
adduct formation. In addition, in the case
of female BALB/c mice given 4-ABP, the
low level ofkidney microsomal activation
(compared to males) may contribute to the
low DNA adduct levels (15).
In three instances, 4-ABP in female
mouse liver, DEN in male rat liver, and
NNK in male rat lung, the profiles for
DNA adducts and tumor incidences were
supralinear (Figure 5, A curves). In these
situations, profiles for tumors and DNA
adducts were similar, although thepostulated
underlying mechanisms for lack oflinearity
may have been different. For example, a
metabolic saturation for 4-ABP activation
may have occurred at the higher doses in
female mice. In male rats given NNK, a
high-affinity activation pathway with a low
Km for NNK is postulated to saturate at
higher doses (21). For both NNK and
DEN the higher doses were also considered
to induce toxicity and cell proliferation
that suppressed DNA adduct formation
and tumorigenesis (20,21).
Table 1. Different patterns of rodent tumorigenesis and DNA adduct formation during chronic administration of
chemical carcinogens at multiple dose levels.
A- Supralinear B - Linear C - Sublinear D -Low
Compound Species Sex Tissue Tumors Adducts Tumors Adducts Tumors Adducts Tumors Adducts
2-AAF Mouse F Liver * *
2-AAF Mouse F Bladder * *
4-ABP Mouse M Liver * *
4-ABP Mouse M Bladder * *
4-ABP Mouse F Liver * *
4-ABP Mouse F Bladder * *
AFB1 Rat M Liver * *
DEN Rat M Liver * *
NNK Rat M Lung * *
Abbreviations: 2-AAF, 2-acetylaminofluorene; 4-ABP, 4-aminobiphenyl; AFB1, aflatoxin B1; DEN, diethylni-
trosamine; NNK, nicotine-derived nitrosoketone; F, female; M, male.
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In two instances, although DNA
adduct formation was linear at all doses,
tumorigenesis was sublinear (Figure 5, C
curve) with no tumors formed at the lower
doses but a significant jump to a high
tumor incidence rate at higher dose levels.
This occurred in the bladders of female
mice given 2-AAF and male mice given 4-
ABP. In the case of 2-AAF in the female
mouse bladder, cell proliferation has been
shown to be a necessary prerequisite for
tumorigenesis (12,13). Although specific
cell proliferation data are not available for
male mice given 4-ABP, bladder hyperplasia
(14) increased relative to dose and was
highest at the tumorigenic doses (55-220
ppm).
Ofthe nine different biologic situations
for which evidence has been considered
above, profiles for DNA adduct formation
reflected profiles for tumorigenesis in five
cases, and in these instances linearity with
dose for both tumors and DNA adducts
appeared to be the norm at the lowest
doses. In two situations the levels of DNA
adducts formed were low, presumably
below the threshold for extensive tumorige-
nesis. In two other situations, even though
DNA adducts were linear, tumors were not
formed at the lower doses; tumorigenesis
appears to have required cell proliferation,
in addition to DNA adduct formation, and
this occurred only at the higher doses.
In condusion, the chronic-dosing studies
presented here indicate that DNA adduct
formation is likely to be linear with dose,
particularly at low, nontoxic doses.
Tumorigenesis, however, may require fac-
tors in addition to DNA adduct formation,
that are likely to be tissue-specific, and may
include metabolic saturation, cell prolifera-
tion, and other manifestations oftoxicity.
REFERENCES
1. Miller EC. Some current perspectives on chemical carcinogene-
sis in humans and experimental animals. Cancer Res
38:1479-1496 (1978).
2. Miller JA. Carcinogenesis by chemicals: an overview. Cancer
Res 30:559-576 (1970).
3. Beland FA, Poirier MC. DNA adducts and carcinogenesis. In:
Pathobiology of Neoplasia (Sirica AE, ed). New York:Plenum
Press, 1989;57-80.
4. Yuspa SH, Poirier MC. Chemical carcinogenesis: from animal
models to molecular models in one decade. Adv Cancer Res
50:25-70 (1988).
5. Poirier MC, HuntJM, True BA, Laishes BA, YoungJF, Beland
FA. DNA adduct formation, removal and persistence in rat
liver during one month of feeding 2-acetylaminofluorene.
Carcinogenesis 5:1591-1596 (1984).
6. Boucheron JA, Richards?n FC, Morgan PH, Swenberg JA.
Molecular dosimetry of0 -ethyldeoxythymidine in rats contin-
uously exposed to diethylnitrosamine. Cancer Res
47:1577-1581 (1987).
7. Swenberg JA, Fedtke N, Fennel TR, Walker VE. Relationships
between carcinogen exposure, DNA adducts and carcinogene-
sis. In: Progress in Predictive Toxicology (Clayson DB, Munro
IC, Shubik P, Swenberg JA, eds). Amsterdam:Elsevier/North
Holland Biomedical Press, 1990;161-184.
8. Belinsky SA, White CM, Boucheron JA, Richardson FC,
Swenberg JA, Anderson M. Accumulation and persistence of
DNA adducts in respiratory tissue of rats following multiple
administrations ofthe tobacco specific carcinogen 4-(N-methyl-
N-nitrosamino)- 1-(3-pyridyl)- 1-butanone. Cancer Res
46:1280-1284 (1986).
9. Wild CP, Garner RC, Montesano R, Tursi F. Aflatoxin Bi binding to plasma albumin and liver DNA upon chronic
administration to rats. Carcinogenesis 7:853-858 (1986).
10. Poirier MC, Fullerton NF, Kinouchi T, Smith BA, Beland FA.
Comparison between DNA adduct formation and tumorigene-
sis in livers and bladders ofmice chronically fed 2-acetylamino-
fluorene. Carcinogenesis 12:895-900 (1991).
11. Beland FA, Fullerton NF, Smith BA, Poirier MC. DNA adduct
formation and aromatic amine tumorigenesis. Prog Clin Biol
Res 374:79-92 (1992).
12. Staffa JA, Mehlman MA. Innovations in cancer risk assessment
(EDO study). J Environ Pathol Toxicol 3:1-246 (1979).
13. Cohen SM, Ellwein LB. Proliferative and genotoxic cellular
effects in 2-acetylaminofluorene bladder and liver carcinogene-
sis: biological modeling of the EDOI study. Toxicol Appl
Pharmacol104:79-93 (1990).
14. Schieferstein GJ, Littlefield NA, Gaylor DW, Sheldon WG,
Burger GT. Carcinogenesis of 4-aminobiphenyl in
BALB/cStCrlfC3Hf/Nctr mice. Eur J Cancer Clin Oncol
21:865-873 (1985).
15. Degawa M, Namiki N, Miura S, Ueno H, Hashimoto Y. A
male-specific renal cytochrome P450 isozyme(s) responsible for
mutagenic activation of 3-methoxy-4-aminoazobenzene in
mice. Biochem Biophys Res Commun 152:843-848 (1988).
16. Wogan GN, Paglialunga S, Newberne PM. Carcinogenic
effects oflow dietary leveTs ofaflatoxin B in rats. Food Cosmet
Toxicol 12:681-685 (1974).
17. Buss P, Caviezel M, Lutz WK. Linear dose-response relation-
ship for DNA adducts in rat liver from chronic exposure to
aflatoxin B . Carcinogenesis 11:2133-2135 (1990).
18. Peto R, Gray R, Brantom P, Grasso P. Effects on 4080 rats of
chronic ingestion of N-nitrosodiethylamine or N-nitrosodi-
methylamine: a detailed dose-response study. Cancer Res
51:6415-6451 (1991).
19. Swenberg JA, Richardson FC, Boucheron JA., Deal FH,
Belinsky SA, Charbonneau M, Short BG. High- to low-dose
extrapolation: critical determinants involved in the dose
response of carcinogenic substances. Environ Health Perspect
76:57-63 (1987).
20. Deal FH, Richardson FC, Swenberg JA. Dose-response of
hepatocyte replication in rats following continuous exposure to
diethylnitrosamine. Cancer Res 49:6985-6988 (1989).
21. Belinsky SA, Foley JF, White CM, Anderson MW, Maronpot
RR. Dose-response relationship between 0 -methylguanine
formation in Clara cells and induction ofpulmonary neoplasia
in the rat by 4-(methylnitrosoamino)-1-(3-pyridyl)-l-
butanone. Cancer Res 50:3772-3780 (1990).
22. Belinsky SA, Walker VE, Maronpot RR, Swenberg JA,
Anderson MW. Molecular dosimetry of DNA adduct forma-
tion and cell toxicity in rat nasal mucosa following exposure to
the tobacco specific nitrosamine 4-(N-methyl-N-nitrosamino)-
1-(3-pyridyl)-1-butanone and their relationship to induction of
neoplasia. Cancer Res 47:6058-6065 (1987).
Volume 102, Supplement 6, October 1994 165